Dr. Eddy Wu is the Founder, Chairman and CEO of Arctic Vision.
Dr. Wu is a committed and proactive professional with a highly successful local and global background in basic science research, clinical development, medical affairs, health economics and commercialization throughout the whole development circle of drugs & devices. Before he founded Arctic Vision, he was the Head of Terns China Biotechnology where he was responsible for directing and overseeing all aspects of R&D activities as well as general management responsibilities. Before Terns, he was the Executive Director at Allergan China where he was responsible for Allergan's overall R&D, clinical, medical and portfolio strategy for China. Previous to his work at Allergan, he was based in Novartis Basel headquarter, Hong Kong, and Taiwan and held various positions with increasing responsibilities and gained in first-hand global experience.
Besides his extensive experience in the healthcare industry, Dr. Wu also owns multiple social titles such as the Senior Fellow of Social Enterprise Research Academy, the Outstanding Young Entrepreneur of Guangdong-HK-Macao Bay Area, and Economic Innovator in the New Era.
Dr. Wu graduated with a bachelor's degree in Biochemistry from the Hong Kong University of Science and Technology (HKUST), where he also obtained his Ph.D. in Biochemistry. He also holds 14 patents and 23 academic publications.
York Chen M.D., EMBA
Chief Commercial Officer
York Chen M.D., EMBA
Chief Commercial Officer
York Chen brings 21 years sales and marketing experience focusing in ophthalmic products. Before joining Arctic Vision, he headed Allergan China's eye care business with full profit & loss responsibility of more than 10 products (Ozurdex, Ganfort, Lumigan, Combigan, Refresh Tears, etc.), covering four different treatment area (Retina/Glaucoma/Stac/Tears). Previously, he was the National Sales Manager at Alcon, leading the sales for multiple projects. Earlier in his career, York served at MSD and Boehringer Ingelheim with extensive experience in management of sales, marketing, distributors, private hospitals, and key accounts.
York graduated from Shanghai JiaoTong university with a bachelor's degree in stomatology and obtained his EMBA from China Europe International Business School (CEIBS).
Qing Liu M.D., Ph.D.
Chief Medical Officer
Qing Liu M.D., Ph.D.
Chief Medical Officer
Dr. Qing Liu has 18 Years of clinical, scientific research and industry experience of ophthalmology. Before joining Arctic Vision, she served as Head of Clinical Development & Medical Affairs for Alcon Greater China region, and Medical Director of Alcon Asia Pacific Region, following her roles as Head of Eye Care Medical Affairs in Allergan China, and Scientific Lead for Glaucoma in Allergan Asia Pacific Region, where she has led and driven the successful clinical development and launch of a wide range of ophthalmic drugs, devices and OTC products.
Dr. Liu completed the clinical training of Ophthalmology in Wuhan Tongji Medical College in her early career, and was selected to join the European Commission Marie-Curie Research Training Networks for Retina Neurobiology-Vision Regulation research, and received her PhD from Leipzig University of Germany.
Simon TsangPh.D.
Chief Business Officer
Simon TsangPh.D.
Chief Business Officer
Simon joined Arctic Vision as Chief Business Officer in 2020. He is also an Operating Partner for Pivotal bioVentures. For nearly 20 years, Simon has had helped organizations create, develop, and partner their most innovative programs or acquire strategic assets.
Before joining Arctic Vision, Simon has held strategy and business development leadership roles at 28-7, Tesaro, MedImmune/AstraZeneca, Amgen, Constellation, Massachusetts General Hospital, and L.E.K. Consulting. He has helped those companies transform from R&D to commercial stage, build virtual pipelines, make their first forays into emerging markets, and aggressively move into new therapeutic areas of focus. Simon's projects have spanned pharmaceuticals, software, and medical devices across many therapeutic areas. His transactional expertise encompasses M&A, global and regional strategic collaborations, co-promotions, platform partnering, and spin-outs.
Simon received his Ph.D. in Biophysics from Harvard and B.S. in Molecular Biology from the University of California, San Diego.
Ping ChengCA/CFA
Vice President, Finance
Ping ChengCA/CFA
Vice President, Finance
Ms. Ping Cheng has almost 20 years of experience of financial management, investing and consulting. Before joining Arctic Vision, she has worked as the Finance VP of Ark Biosciences Inc. She started her career as a chartered accountant and corporation tax consultant in Ernest & Young's financial services office in London after her University degree, and then joined Credit Suisse's UK securities business as an Equity Analyst. In 2011, She became the Head of Shanghai office of DBS Vickers as its lead analyst covering the China Insurance sectors. Ms. Cheng also worked in corporate buy-out for some China's largest industrial conglomerates including Fosun International.
Ms. Cheng graduated from School of Management, University of Bradford (UK) with a Bachelor's degree in 2001. She is qualified as a Chartered Accountant with Institute of Chartered Accountant of Scotland (ICAS) and has a CFA designation.
Katherine HeNYSBA
Senior Director, Legal
Katherine HeNYSBA
Senior Director, Legal
Ms. Katherine He has 9 years' working experience in capital market. Before joined Arctic Vision, she was a senior counsel of a prestigious"Red Circle"law firm. Ms. Katherine He closed dozens of onshore and offshore IPO, PE/VC, M&A deals for biotech companies and companies from other industries.
Ms. Katherine He graduated from University of Chicago Law School and Fudan Law School with US and China master's degrees in law. She is qualified to practice law in New York State.
SCIENTIFIC ADVISORY BOARD
Harminder Singh Dua CBE
President, European Association for Vision and Eye Research Foundation Chair of ophthalmology at University of Nottingham
Harminder Singh Dua CBE
President, European Association for Vision and Eye Research Foundation Chair of ophthalmology at University of Nottingham
Professor Haminder is the Chairman of Ophthalmology and vision science in University of Nottingham, UK, President of European Association for Vision and Eye Research Foundation and Editor of Journal of EuCornea. He is a Cornea specialist with most famous contribution of discovery of a previously undetected layer (Pre-Decemet layer – also dubbed Dua's Layer) of the human cornea in 2013. He served as president of EVER, EuCornea and the Royal College of Ophthalmologists previously, and as Editor-in-chief of the British journal of ophthalmology. He has been appointed by Her Majesty Queen Elizabeth II as Commander of the Most Excellent Order of the British Empire (CBE) for Services to Ophthalmology.
Scott William Cousins MD
Director of the Duke Center for Macular Diseases, Vice Chair of Ophthalmology at Duke University Previous Imagen CSO
Scott William Cousins MD
Director of the Duke Center for Macular Diseases, Vice Chair of Ophthalmology at Duke University Previous Imagen CSO
Professor Scott William Cousins is Vice Chair for Research and Director of the Duke Center for Macular Diseases at Duke Eye Center, Duke University School of Medicine, Durham, North Carolina, USA. He is a clinician scientist who specializes in the diagnosis and treatment of macular diseases, and is active in both laboratory and clinical research. He is actively engaged in scientific and translational studies, as well as serving as assisting in the development of many innovative therapies for the treatment of macular diseases. He served on the National Eye Council, where he advised the Director of the National Eye Institute of the National Institutes of Health. He has served as PI for numerous phase 1-3 clinical trials in AMD, diabetic retinopathy, and other retinal disorders, and as member of data safety monitoring committees for numerous pharmaceutical and biotechnology startup companies. In 2010, Professor Cousins was named as one of the top 34 ophthalmologists in the United States.
Xinghuai SunMD
President-elect of China Ophthalmology Society
Xinghuai SunMD
President-elect of China Ophthalmology Society
Chairman of Department of Ophthalmology & Visual Science of Shanghai Medical College, Fudan University, and President-elect of Chinese Ophthalmology Society. He is renowned for his achievements in glaucoma clinical and research work as well as vision science. He has been served as President of Eye & ENT Hospital of Fudan University from 2005-2016, and is the Director of NHC/Chinese Academy of Medical Sciences Key Laboratory of Myopia, Governor of the World Glaucoma Association Board. His contributions to ophthalmology have been recognized with numerous honors, including Second prize of China National Science and Technology Progress Award, Award for excellent ophthalmologist in China, Asia-Pacific Academy of Ophthalmology Distinguished Service Award.
BOARD OF DIRECTORS
Eddy Wu
Chairman
Eddy Wu Chairman
Dr. Eddy Wu is the Founder, Chairman and CEO of Arctic Vision.
Dr. Wu is a committed and proactive professional with a highly successful local and global background in basic science research, clinical development, medical affairs, health economics and commercialization throughout the whole development circle of drugs & devices. Before he founded Arctic Vision, he was the Head of Terns China Biotechnology where he was responsible for directing and overseeing all aspects of R&D activities as well as general management responsibilities. Before Terns, he was the Executive Director at Allergan China where he was responsible for Allergan's overall R&D, clinical, medical and portfolio strategy for China. Previous to his work at Allergan, he was based in Novartis Basel headquarter, Hong Kong, and Taiwan and held various positions with increasing responsibilities and gained in first-hand global experience.
Besides his extensive experience in the healthcare industry, Dr. Wu also owns multiple social titles such as the Senior Fellow of Social Enterprise Research Academy, the Outstanding Young Entrepreneur of Guangdong-HK-Macao Bay Area, and Economic Innovator in the New Era.
Dr. Wu graduated with a bachelor's degree in Biochemistry from the Hong Kong University of Science and Technology (HKUST), where he also obtained his Ph.D. in Biochemistry. He also holds 14 patents and 23 academic publications.
Meng Gao
Director
Meng GaoDirector
Meng GAO is the Chief Investment Officer of Nan Fung Group and Managing Partner of Pivotal bioVenture Partners.
He is responsible for developing the Group's strategic initiatives including Nan Fung Life Sciences and overseas real estate platform, as well as overseeing the Group's financial investment activities. Mr. Gao is also a Partner and Director of New Frontier Group, an investment platform co-founded by Nan Fung.
Prior to joining the Group, Mr. Gao was a Managing Director at Blackstone's Private Equity Group in Hong Kong where he was involved in a number of transactions across multiple industries. Before joining Blackstone, he was a Senior Vice President at Oaktree Capital Management where he was involved in sourcing, structuring and executing private equity investments in China. Prior to that, Mr. Gao was an investment banker with Credit Suisse and JPMorgan in New York.
Mr. Gao received a Bachelor of Economics degree from Peking University, an M.A. from Yale University and an M.B.A. with Honors from the Wharton School of the University of Pennsylvania.
Dan LIU
Director
Dan LIUDirector
Dr. Dan LIU is the Managing Partner of Pivotal bioVenture Partners, he leads the investment team and oversees business operations in Great China. He has previously served as a Senior Partner, Managing Partner and Investment Committee Member in several funds at CDH Investments, in charge of healthcare investments. Dr. Liu has led tens of successful investments, such as GemPharmatech (688046.SH), HitGen (688222.SH), I-Mab (IMAB.O), Maixin (acquired by BSBE), and serves on the boards of several public and private companies. Prior to CDH, Dr. Liu worked at Bain & Company, serving in management consulting leadership team, where he was the key professional of Asia Healthcare practice. Together Dr. Liu has 20 years of experience in many fields of Life Sciences, including research, business, consulting and investment. Dr. Liu also serves as a member in several industry association panels and boards.
Lu Huang
Director
Lu HuangDirector
Dr. Huang is Managing Director of Morningside Ventures and leads Morningside's life science/healthcare investment team in Greater China. Dr. Huang has over 20 years combined experience in the industry as a clinician and a VC investor. Since joining Morningside in 2003, Dr. Huang has led over 3 dozens life-science/healthcare investments in China, Europe and the North America, representing Morningside on various company boards. Morningside life-science/healthcare investments cover sectors across bio-pharmaceutical, medical devices, IVD, healthcare services, healthcare IT, healthcare insurance and etc.
Prior to joining Morningside, Dr. Huang was with Continuum Health Partners in New York City, which organization provides integrated healthcare management services throughout the New York metropolitan region.
Dr. Huang holds her medical degree from Shanghai Jiao Tong University Medical School (Former Shanghai Second Medical University), trained and practiced in Obstetrics/Gynecology; and her M.B.A. degree from St. John's University, New York.
Roy Xie
Director
Roy XieDirector
Mr. Roy Xie is a partner at Loyal Valley Capital and leads Loyal Valley Capital's life science and healthcare investment team. Roy has extensive healthcare investment experience, selected investment projects including: Junshi Biosciences, Akesobio, RemeGen, INNOCARE, Allist, CARsgen, OBiO, etc.
Prior to joining Loyal Valley Capital, Roy served as an Investment Director at Oriza Cowin Capital. Roy graduated from Southeast University with a Master's degree in Biomedical Engineering.
@1Suite 906-908, 9F, Tower II, Century Link, 1196 Century Avenue, Shanghai, China
@2Suite A09, 10th Floor, Twin Towers (East), B 12 Jianguomenwai Avenue, Beijing, China
@3Room 1111, 11F., OfficePlus @Prince Edward 794-802 Nathan Road, Kowloon, Hong Kong
@4Suite Level 5 63 Pirie Street, Adelaide, SA 5000, Australia